𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses

✍ Scribed by Boo Edgar; Carl G. Regårdh; Per Lundborg; SÖRen Romare; Gunnar Nyberg; Ola Rönn

Publisher
John Wiley and Sons
Year
1987
Tongue
English
Weight
607 KB
Volume
8
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

✦ Synopsis

The objective of this single-dose study was to evaluate the pharmacokinetics and haemodynamic changes in healthy male subjects following the administration of three oral ( 5 , 15, and 40mg) and two intravenous (1 and 3mg) doses of felodipine, a new calcium antagonist with a selective effect on the peripheral resistance vessels.

Felodipine was rapidly absorbed within 1 h when administered as an oral solution, but underwent extensive presystemic elimination. The systemic availability varied between 10 and 23 per cent. The disposition was adequately described by a two-compartment model: the disposition was essentially dose-independent up to 40 mg orally and 3 mg intravenously.

Felodipine produced significant dose-dependent reduction of diastolic blood pressure and a significant reflexogenic increase in heart rate, without having any major effect on systolic blood pressure. These changes indicate that felodipine acts predominantly as an arteriodilator. The decrease in diastolic blood pressure and increase in heart rate were closely correlated with the plasma concentrations of unchanged felodipine, being maximal at 0.5 h and lasting for at least 4 h after the highest dose.

📜 SIMILAR VOLUMES

Single intravenous dose and steady-state
Single intravenous dose and steady-state oral dose pharmacokinetics of nicardipine in healthy subjects
✍ John G. Wagner; Teck L. Ling; Edward J. Mroszczak; Donna Freedman; Ann Wu; Bee H 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 617 KB

Nicardipine HCI oral doses (10-40 mg) were administered sequentially to six healthy subjects. For each regimen the capsule dose was administered every 8 hours (q 8 h) for 3 days and the plasma profiles of nicardipine and its pyridine analogue (M5) were determined following the last dose on day 4. St

Pharmacokinetics of fluvoxamine maleate
Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects
✍ M. H. De Vries; J. Van Harten; P. Van Bemmel; M. Raghoebar 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 2 views

The pharmacokinetics of fluvoxamine after single oral administration of 25, 50, and 100mg fluvoxamine maleate was studied in a three-way cross-over study in 12 healthy male subjects. Fluvoxamine was administered orally in a solution. For doseproportionality, AUC, and C,-dose relationships were evalu

Pharmacokinetics of deramciclane in dogs
Pharmacokinetics of deramciclane in dogs after single oral and intravenous dosing and multiple oral dosing
✍ Harri Kanerva; Hannele Huuskonen; Anneli Alhonen-Raatesalmi; Timo Nevalainen; Ar 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB 👁 2 views

The pharmacokinetics of a new serotonin 5-HT 2 antagonist, deramciclane, was studied. Single oral doses of 1, 3, 6 and 10 mg kg -1 and intravenous doses of 1, 3 and 6 mg kg -1 were administered in beagle dogs. Moreover, the steady state pharmacokinetics of 1, 3 and 6 mg kg -1 doses were studied. Der

Pharmacokinetics of benzydamine after in
Pharmacokinetics of benzydamine after intravenous, oral, and topical doses to human subjects
✍ G. A. Baldock; R. R. Brodie; L. F. Chasseaud; T. Taylor; L. M. Walmsley; B. Cata 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 540 KB

## Abstract The pharmacokinetics of the anti‐inflammatory drug benzydamine were determined after intravenous infusion of 5 mg to six healthy male subjects. Benzydamine was characterized as a drug of relatively low systemic clearance (ca. 160 ml min^−1^) but high volume of distribution (ca. 1101); t

PHARMACOKINETICS AND SAFETY OF SINGLE IN
PHARMACOKINETICS AND SAFETY OF SINGLE INTRAVENOUS AND ORAL DOSES OF DOLASETRON MESYLATE IN HEALTHY WOMEN
✍ ANTHER C. F. KEUNG; HÉLÈNE LANDRIAULT; MARC LEFEBVRE; DENIS GOSSARD; ELLEN E. DE 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 2 views

Twenty-four healthy women received 2´4 mg kg 71 dolasetron mesylate (1´8 mg kg 71 dolasetron base) by a 10 min intravenous administration and by oral administration. Pharmacokinetics of dolasetron and of its active reduced metabolite MDL 74 156 were monitored for 48 h in plasma. Urine was collected